1,048
Participants
Start Date
January 11, 2011
Primary Completion Date
December 15, 2012
Study Completion Date
December 15, 2012
Tivantinib
Tivantinib 720 mg daily as 3 x 120 mg oral tablets given twice a day
Placebo
Tivantinib Placebo tablets given twice a day
Erlotinib
Erlotinib 150 mg oral tablets, given once a day
Grenoble
Lima
Lima
Lima
St Leonards
Duffel
Brasschaat
Greenslopes
Næstved
Salzburg
Helmond
Enschede
New York
Orbassano
Berlin
The Bronx
Goshen
Cuneo
Berlin
Prague
Caen
Buffalo
A Coruña
A Coruña
Santiago de Compostela
Harrisburg
Philadelphia
Newark
Rozzano
Gainesville
Milan
Leesburg
Monza
Hamburg
Towson
Fairfax
Woodbridge
Arlington
Winchester
Großhansdorf
Sondalo
Midlothian
Richmond
Besançon
Cremona
Madrid
Madrid
Novara
Málaga
Columbia
Spartanburg
Greenville
Greenville
Brest
Greenville
Easley
Marietta
Austell
Carrollton
Cartersville
Douglasville
Atlanta
Hanover
Toulouse
Krakow
Olsztyn
Porta Westfalica
Pensacola
Oviedo
Miami Beach
Aviano
Fort Myers
Kassel
Rennes
Padua
Rzeszów
Vigo
Tours
Nashville
Chattanooga
Knoxville
Memphis
Bartlett
Germantown
San Cristóbal de La Laguna
Southaven
Rancho Mirage
Seville
Modena
Seville
Parma
Cleveland
Guadalajara
Essen
Cincinnati
Valencia
Carmel
Fishers
Greenfield
Indianapolis
Indianapolis
Goshen
Indianapolis
Rheine
Barakaldo
Zaragoza
Florence
Cologne
Leverkusen
Pardubice
Mainz
Minneapolis
Livorno
Lille
Chicago
St Louis
Monterrey
Oaxaca City
Mannheim
Omaha
Grand Island
Pierre-Bénite
Oaxaca City
Bari
Ostrava
Szczecin
Esslingen am Neckar
Löwenstein
Paris
Paris
Dallas
Fort Worth
Fort Worth
Karlsruhe
Villingen-Schwenningen
Kyle
Round Rock
San Marcos
Round Rock
Austin
Austin
Cedar Park
Austin
Austin
Aurora
Littleton
Lone Tree
Napoli
Parker
Denver
Denver
Lakewood
Thornton
Boulder
München
Longmont
Colorado Springs
Colorado Springs
München
Gauting
Prabuty
Avellino
Salt Lake City
Tucson
Tucson
Tucson
Albuquerque
Henderson
Henderson
Las Vegas
Las Vegas
Las Vegas
Joinville
Los Angeles
Palermo
Santa Monica
Rancho Mirage
Villejuif
Catania
Tualatin
Portland
Portland
Portland
Portland
Eugene
Springfield
Seattle
Vancouver
Vancouver
Yakima
Bad Berka
Moscow
Moscow
Saint Petersburg
Saint Petersburg
Saint Petersburg
Craiova
Tula
Kursk
Pyatigorsk
Cluj-Napoca
Oradea
Izhevsk
Chelyabinsk
Veliky Novgorod
Tyumen
Irkutsk
Santiago
Santiago
Santiago
Santiago
Joinville
Tucson
Oxnard
Lexington
Louisville
Latham
Kettering
Buenos Aires
San Miguel de Tucumán
Viedma
Camperdown
Kogarah
Perth
Wollongong
Woodville
Brussels
Ijuí
Porto Alegre
São Paulo
Ústí nad Labem
Marseille
Saint-Priest-en-Jarez
Strasbourg
Erfurt
München
Ancona
Torino
Mexico City
Mexico City
Amsterdam
Arequipa
Lima
Lublin
Opole
Poznan
Torun
Wałbrzych
Novosibirsk
Madrid
Lund
Boston
East Orange
Hershey
Dallas
Rosario
Córdoba
Wels
Salvador
Rio de Janeiro
Passo Fundo
Passo Fundo
Porto Alegre
São Paulo
Edmonton
Surrey
Victoria
Winnipeg
London
Thunder Bay
Toronto
Montreal
Montreal
Québec
Toronto
Herlev
Odense
Halle
Deszk
Gyula
Mátraháza
Székesfehérvár
Szolnok
Perugia
Roma
Sassari
Sora
Bystra
Poznan
Alicante
Barcelona
Barcelona
Manresa
Palma de Mallorca
Sabadell
Linköping
Guildford
Aberdeen
Glasgow
London
London
Manchester
Nottingham
Sheffield
Lead Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
INDUSTRY
Daiichi Sankyo
INDUSTRY